选择性HDAC6抑制在创伤性脑损伤与失血性休克大动物模型中减少病灶体积与脑肿胀
该研究在体外小鼠海马细胞氧糖剥夺/复氧模型中观察VPA(4 mmol/L)与ACY-1083(30、300 nmol/L)对细胞活力的影响,并在猪创伤性脑损伤合并失血性休克模型中随机分为三组(每组n=5):生理盐水组、生理盐水+丙戊酸(150 mg/kg)组、生理盐水+ACY-1083(30 mg/kg)组,6小时后取脑组织评估病灶体积与脑肿胀。体外实验中两种HDAC抑制剂均显著改善细胞活力,ACY-1083剂量依赖性抑制HIF-1α表达并上调磷酸化mTOR与HSP70。体内实验中VPA组与ACY-1083组的病灶体积和脑肿胀均小于生理盐水组,两治疗组之间无差异。作者结论为选择性抑制HDAC6在创伤性脑损伤合并失血性休克大动物模型中与非选择性HDAC抑制具有同等神经保护作用。
要点
- 猪创伤性脑损伤合并失血性休克模型中,生理盐水+丙戊酸(150 mg/kg)组与生理盐水+ACY-1083(30 mg/kg)组的病灶体积和脑肿胀均小于生理盐水组(每组n=5)。
- 丙戊酸组与ACY-1083组之间病灶体积和脑肿胀无差异,提示选择性HDAC6抑制与非选择性HDAC抑制神经保护作用相当。
- 体外氧糖剥夺/复氧模型中,VPA(4 mmol/L)与ACY-1083(30、300 nmol/L)均显著改善小鼠海马细胞活力。
- ACY-1083剂量依赖性抑制HIF-1α表达并上调磷酸化mTOR与热休克蛋白70。
- 该研究为动物实验,结果尚不能直接转化为临床用药方案。
适用人群与场景
- 体外:小鼠海马细胞,接受氧糖剥夺(0% O2、无糖无血清培养基,18小时)与复氧(21% O2、正常培养基,4小时)。
- 体内:猪,接受创伤性脑损伤合并失血性休克造模。
处置流程与药物剂量
- 体外分组:不加药、VPA 4 mmol/L、ACY-1083 30 nmol/L或300 nmol/L。
- 体内随机三组(每组n=5):(i)生理盐水(3倍失血量);(ii)生理盐水(3倍失血量)+VPA 150 mg/kg;(iii)生理盐水(3倍失血量)+ACY-1083 30 mg/kg。
- 给药6小时后取脑组织评估病灶体积与脑肿胀。
研究设计与关键结果
- 研究类型:体外细胞实验+猪大动物随机对照实验。
- 体外:VPA(4 mmol/L)与ACY-1083(30、300 nmol/L)均显著改善细胞活力;ACY-1083剂量依赖性抑制HIF-1α表达并上调磷酸化mTOR与HSP70。
- 体内(每组n=5):VPA组与ACY-1083组的病灶体积和脑肿胀均小于生理盐水组;VPA组与ACY-1083组之间无差异。
证据类型、等级与局限
- 证据类型:动物实验(体外细胞实验+猪模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在创伤性脑损伤合并失血性休克大动物模型中,选择性抑制HDAC6与非选择性HDAC抑制具有同等神经保护作用。
- 该研究为动物实验,原文未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nonselective histone deacetylase (pan-HDAC) inhibitors, such as valproic acid (VPA), have demonstrated neuroprotective properties in trauma models. However, isoform-specific HDAC inhibitors may provide opportunity for more effective drug administration with fewer adverse effects. We investigated HDAC6 inhibition with ACY-1083 in an in vitro and an in vivo large animal model of injury.
METHODS: Mouse hippocampal cells were subjected to oxygen-glucose deprivation (0% O2, glucose-free and serum-free medium, 18 hours) and reoxygenation (21% O2, normal culture media, 4 hours) with/without VPA (4 mmol/L) or ACY-1083 (30 nmol/L, 300 nmol/L). Cell viability was measured by methylthiazolyl tetrazolium assay. Expression of hypoxia-inducible factor-1α, heat shock protein 70, and effectors in the phosphoinositide-3 kinase/mammalian target of rapamycin pathway were measured by Western blot analysis. Additionally, swine were subjected to combined traumatic brain injury and hemorrhagic shock and randomized to three treatment groups (n = 5/group): (i) normal saline (NS; 3× hemorrhage volume); (ii) NS + VPA (NS; 3× hemorrhage volume, VPA; 150 mg/kg), and (iii) NS + ACY-1083 (NS; 3× hemorrhage volume, ACY-1083; 30 mg/kg). After 6 hours, brain tissue was harvested to assess lesion size and brain swelling.
RESULTS: Significant improvement in cell viability was seen with both HDAC inhibitors in the in vitro study. ACY-1083 suppressed hypoxia-inducible factor-1α expression and up-regulated phosphorylated mammalian target of rapamycin and heat shock protein 70 in a dose-dependent manner. Lesion size and brain swelling in animals treated with pharmacologic agents (VPA and ACY-1083) were both smaller than in the NS group. No differences were observed between the VPA and ACY-1083 treatment groups.
CONCLUSIONS: In conclusion, selective inhibition of HDAC6 is as neuroprotective as nonselective HDAC inhibition in large animal models of traumatic brain injury and hemorrhagic shock.
参考来源
- Nikolian VC, Dennahy IS, Weykamp M, et al. Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock. J Trauma Acute Care Surg. 2019. PMID: 30399139. doi:10.1097/TA.0000000000002119
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。